Forbion

Forbion company information, Employees & Contact Information

Explore related pages

Related company profiles:

Forbion was born out of ABN AMRO Capital Life Sciences in 2000. Six years later, we transitioned to Forbion Capital Partners. Today, to emphasize our value-add beyond merely providing capital, we are simply known as Forbion. For more than two decades, our investment team has built an impressive track record of sourcing, building and guiding life-sciences companies resulting in many breakthrough therapies and valuable exits. Forbion currently manages over €2.3 bn across ten funds. As of October 2022, Forbion holds 43 active portfolio companies bringing its investments to 95 companies to date with 46 employees. Forbion’s investors include the European Investment Fund (EIF), notably through its European Recovery Programme (ERP), LfA, the Dutch Venture Initiative (DVI) and AMUF facilities, and the Kreditanstalt für Wiederaufbau (KFW) through the ERP – Venture Capital Fondsfinanzierung facility.

Company Details

Employees
79
Founded
-
Address
Gooimeer 2-35, Naarden,1411 Dc,netherlands
Phone
+31 35 699 30 00
Email
in****@****ion.com
Industry
Venture Capital And Private Equity Principals
NAICS
Miscellaneous Intermediation
HQ
Naarden
Looking for a particular Forbion employee's phone or email?

Forbion Questions

News

Jon Edwards, PhD, Appointed Partner - GlobeNewswire

Jon Edwards, PhD, Appointed Partner GlobeNewswire

2025 Biotech Fundraising Trends: A Two-Speed Capital Market - BioBuzz

2025 Biotech Fundraising Trends: A Two-Speed Capital Market BioBuzz

Orbis Medicines launches with €26 million seed financing to transform macrocycle drug development through next-generation orally dosable ‘nCycles’ - Arctic Today

Orbis Medicines launches with €26 million seed financing to transform macrocycle drug development through next-generation orally dosable ‘nCycles’ Arctic Today

Forbion BioEconomy Fund I Raises €164.5M - iGrow News

Forbion BioEconomy Fund I Raises €164.5M iGrow News

Sparrow Pharmaceuticals Announces $95 Million Series B Financing to Advance Targeted Therapy for Type 2 Diabetes - GlobeNewswire

Sparrow Pharmaceuticals Announces $95 Million Series B Financing to Advance Targeted Therapy for Type 2 Diabetes GlobeNewswire

Firm Advises Sofinnova, Novo Holdings, and Forbion on Expedition Therapeutics’ $165 Million Series A Financing - Wilson Sonsini

Firm Advises Sofinnova, Novo Holdings, and Forbion on Expedition Therapeutics’ $165 Million Series A Financing Wilson Sonsini

Forbion points to high investor demand in €1.3B raise for largest haul yet - Fierce Biotech

Forbion points to high investor demand in €1.3B raise for largest haul yet Fierce Biotech

Beyond Biotech podcast 1: Forbion, OMass, PharNext - Labiotech.eu

Beyond Biotech podcast 1: Forbion, OMass, PharNext Labiotech.eu

Forbion-backed biotech raises $138M to develop ALS drug - BioPharma Dive

Forbion-backed biotech raises $138M to develop ALS drug BioPharma Dive

Novameat Raises €17.4M Oversubscribed Series A Round Led by Sofinnova Partners and Forbion - Business Wire

Novameat Raises €17.4M Oversubscribed Series A Round Led by Sofinnova Partners and Forbion Business Wire

AAVantgarde Closes €61 Million Series A Financing to Advance Two Therapeutic Programs into the Clinic - Yahoo Finance

AAVantgarde Closes €61 Million Series A Financing to Advance Two Therapeutic Programs into the Clinic Yahoo Finance

Forbion announces €164.5 M for BioEconomy Fund I - World Bio Market Insights

Forbion announces €164.5 M for BioEconomy Fund I World Bio Market Insights

RA and Forbion back Sparrow’s $95M Series B for type 2 diabetes drug - Endpoints News

RA and Forbion back Sparrow’s $95M Series B for type 2 diabetes drug Endpoints News

Forbion raises more than €2bn for two new funds - European Biotechnology Magazine

Forbion raises more than €2bn for two new funds European Biotechnology Magazine

enGene Holdings (Forbion European Acquisition) - renaissancecapital.com

enGene Holdings (Forbion European Acquisition) renaissancecapital.com

Forbion-backed biotech Progentos debuts with $65M for MS drug - BioPharma Dive

Forbion-backed biotech Progentos debuts with $65M for MS drug BioPharma Dive

Sitala, backed by Forbion and OrbiMed, seals $670M deal for Fosun immune disease drug - Fierce Biotech

Sitala, backed by Forbion and OrbiMed, seals $670M deal for Fosun immune disease drug Fierce Biotech

Forbion announces first close of Forbion Growth Opportunities Fund II at €470 million - GlobeNewswire

Forbion announces first close of Forbion Growth Opportunities Fund II at €470 million GlobeNewswire

Forbion Appoints Nanna Lüneborg as a General Partner - GlobeNewswire

Forbion Appoints Nanna Lüneborg as a General Partner GlobeNewswire

Forbion participates in US financing rounds - European Biotechnology Magazine

Forbion participates in US financing rounds European Biotechnology Magazine

Pheon Therapeutics Launches with $68 Million in Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Solid Tumors - PR Newswire

Pheon Therapeutics Launches with $68 Million in Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Solid Tumors PR Newswire

Local biotech exec joins Dutch VC firm that plans to open first U.S. office in Boston - The Business Journals

Local biotech exec joins Dutch VC firm that plans to open first U.S. office in Boston The Business Journals

Granite Bio Debuts With $100 Million of Capital - BioSpace

Granite Bio Debuts With $100 Million of Capital BioSpace

FRBNU IPO News - Dutch venture firm's SPAC Forbion European Acquisition files for a $100 million IPO - renaissancecapital.com

FRBNU IPO News - Dutch venture firm's SPAC Forbion European Acquisition files for a $100 million IPO renaissancecapital.com

“The Immuno-Oncology Curve” with Dr. Steven O’Day – Guest is Alexander (Lex) Eggermont - Oncodaily

“The Immuno-Oncology Curve” with Dr. Steven O’Day – Guest is Alexander (Lex) Eggermont Oncodaily

Forbion closes first Bioeconomy Fund with US$75m - European Biotechnology Magazine

Forbion closes first Bioeconomy Fund with US$75m European Biotechnology Magazine

Forbion: Life Sciences Venture Firm Raises €1.35 Billion - Pulse 2.0

Forbion: Life Sciences Venture Firm Raises €1.35 Billion Pulse 2.0

Forbion closes final European life sciences funding round at €360M with help from Eli Lilly - Fierce Biotech

Forbion closes final European life sciences funding round at €360M with help from Eli Lilly Fierce Biotech

Dutch life sciences VC firm Forbion raises €2B+ for two new funds: Know more - Silicon Canals

Dutch life sciences VC firm Forbion raises €2B+ for two new funds: Know more Silicon Canals

Tessellate BIO Emerges from Stealth - Yahoo Finance

Tessellate BIO Emerges from Stealth Yahoo Finance

Forbion, with $316M to invest, backs away from medtech as consolidation and regulatory changes depress returns - Fierce Biotech

Forbion, with $316M to invest, backs away from medtech as consolidation and regulatory changes depress returns Fierce Biotech

The Netherlands: Forbion raises over €2bn across two newest funds - Investors in Healthcare

The Netherlands: Forbion raises over €2bn across two newest funds Investors in Healthcare

Netherlands: Forbion elevates Mathias Vinther to partner within its Growth Fund - Investors in Healthcare

Netherlands: Forbion elevates Mathias Vinther to partner within its Growth Fund Investors in Healthcare

Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical Programs of Innovative Therapies in Lysosomal Storage Disorders - Business Wire

Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical Programs of Innovative Therapies in Lysosomal Storage Disorders Business Wire

The Netherlands: Forbion BioEconomy Fund I surpasses €150m target - Investors in Healthcare

The Netherlands: Forbion BioEconomy Fund I surpasses €150m target Investors in Healthcare

Peninsula biotech lands nearly $400 million in fresh funding as it takes schizophrenia drug into mid-stage trial - The Business Journals

Peninsula biotech lands nearly $400 million in fresh funding as it takes schizophrenia drug into mid-stage trial The Business Journals

Forbion co-leads major investment in UK obesity biotech startup - medwatch.com

Forbion co-leads major investment in UK obesity biotech startup medwatch.com

Navigator Medicines Announces $100 Million Series A Financing and In-Licensing of NAV-240, a Potential Best-in-Class Anti-OX40L and Anti-TNFα Bispecific Antibody Therapeutic for Autoimmune Diseases - Business Wire

Navigator Medicines Announces $100 Million Series A Financing and In-Licensing of NAV-240, a Potential Best-in-Class Anti-OX40L and Anti-TNFα Bispecific Antibody Therapeutic for Autoimmune Diseases Business Wire

Genomines Raises $45M Series A to Redefine Global Metal Extraction with Plant-Based Nickel - Business Wire

Genomines Raises $45M Series A to Redefine Global Metal Extraction with Plant-Based Nickel Business Wire

Forbion forges $415m fund - - Global Corporate Venturing

Forbion forges $415m fund - Global Corporate Venturing

NewAmsterdam Pharma Acquires Obicetrapib from Amgen - Business Wire

NewAmsterdam Pharma Acquires Obicetrapib from Amgen Business Wire

Covicept lands Forbion backing for mission to tackle RNA viruses - BioWorld MedTech

Covicept lands Forbion backing for mission to tackle RNA viruses BioWorld MedTech

Forbion growth opportunities fund increases stake in Engene Holdings with $3 million purchase - Investing.com UK

Forbion growth opportunities fund increases stake in Engene Holdings with $3 million purchase Investing.com UK

Forbion Capital Partners launches $208m life sciences fund - MassDevice

Forbion Capital Partners launches $208m life sciences fund MassDevice

Forbion appoints Dr. Carlo Incerti as Operating Partner - European Biotechnology Magazine

Forbion appoints Dr. Carlo Incerti as Operating Partner European Biotechnology Magazine

The Netherlands: Nanna Lüneborg joins Forbion to work on Growth Opportunities Fund - Investors in Healthcare

The Netherlands: Nanna Lüneborg joins Forbion to work on Growth Opportunities Fund Investors in Healthcare

For Up to $1.55B, Amgen Acquires Dezima Pharma - Genetic Engineering and Biotechnology News

For Up to $1.55B, Amgen Acquires Dezima Pharma Genetic Engineering and Biotechnology News

Top Forbion Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant